Physician profile
Cynthia Lin
NPI 1134106388
$1,907.99
in general payments reported to CMS, 2019-2025
17 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $19.14 · 2021: $182 · 2022: $438 · 2023: $561 · 2024: $200 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $44.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.96 |
| Education | $44.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $333.55 | 2021-2023 | |
| Horizon Therapeutics Plc | $290.52 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $236.66 | 2019-2025 | Lokelma, Farxiga |
| Apellis Pharmaceuticals, INC. | $219.91 | 2025 | Empaveli |
| Otsuka America Pharmaceutical, INC. | $174.82 | 2019-2023 | Jynarque |
| Fresenius USA Marketing, INC. | $151.70 | 2022-2024 | Velphoro |
| Bard Peripheral Vascular, INC. | $135.28 | 2019 | |
| Glaxosmithkline, LLC. | $74.57 | 2021-2023 | Benlysta, Jesduvroq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $62.45 | 2023-2024 | Jynarque |
| Amgen INC. | $56.89 | 2024 | Krystexxa |
| Aurinia Pharma U.S., INC. | $49.99 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $30.10 | 2023-2024 | Acthar |
| Travere Therapeutics, INC. | $26.02 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $18.45 | 2022 | |
| Opko Pharmaceuticals, LLC | $16.81 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $15.59 | 2019 | |
| Ardelyx, INC. | $14.68 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.